Company Overview of OncoCyte Corporation
OncoCyte Corporation develops genetically modified stem cells for finding malignant tumors while carrying genes that cause the destruction of the cancer cells. It offers PanC-Dx bladder cancer markers to the performance of cystoscopy. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation operates as a subsidiary of BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502
Founded in 2009
Key Executives for OncoCyte Corporation
Chief Executive Officer and Director
Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc.
Compensation as of Fiscal Year 2015.
OncoCyte Corporation Key Developments
OncoCyte Corporation Announces Management Changes
Jun 16 15
OncoCyte Corporation announced that William Annett has been appointed Chief Executive Officer. Mr. Annett succeeds Joseph Wagner, PhD, who spearheaded the early stages of clinical development of OncoCyte’s product lines. With the departure of Dr. Wagner from the company and the board of the company, Mr. Annett will immediately take responsibility for leading the company through the later stages of clinical trials of OncoCyte’s proprietary, non-invasive diagnostic tests for cancer. Mr. Annett also assumes immediate responsibility for the development and execution of the commercial strategy for OncoCyte’s class of diagnostic tests. Having previously served as Chief Executive Officer of several companies, Mr. Annett brings to OncoCyte extensive experience within the biotechnology and diagnostics industry. In addition, Mr. Annett has held significant management positions at Genentech and Accenture and has worked on the clinical development and commercialization of a wide range of drugs and diagnostics. Mr. Annett’s diagnostics industry experience includes his service as CEO at BioFX Laboratories Inc. Most recently, Mr. Annett was a Managing Director at Accenture where he founded, built, and headed Accenture’s West Coast Life Sciences practice with sales, marketing, and delivery responsibilities for the entire territory.
BioTime, Inc. and OncoCyte Corporation Announce Positive Interim Results from Lung Cancer Study
Jun 4 15
BioTime, Inc. and OncoCyte Corporation have announced positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed samples of a simple blood-based test designed for the early detection of lung cancer. The large, prospective clinical study was conducted by The Wistar Institute. The test was developed in the laboratory of Louise Showe, PhD, professor in the Molecular and Cellular Oncogenesis program of The Wistar Institute's NCI-designated cancer center. As part of the study, clinical investigators used a simple collection system that is approved by the FDA to prepare over 600 peripheral blood samples from patients determined to be at high risk for developing lung cancer based on age and smoking history. These patients were undergoing either low-dose computed tomography (CT) scanning for lung cancer or were recently diagnosed with lung cancer. Wistar scientists then assessed the expression of messenger RNA and micro RNA in the initial training set of 242 samples and developed a classifier of 145 markers (125 mRNAs plus 20 micro RNAs) that most accurately distinguished patients with malignant nodules from those with benign or no findings. The classifier was then assessed in an independent test set of 103 samples. Performance of the classifier was evaluated using several criteria, including Receiver Operating Characteristic (ROC) area under the curve (AUC) analysis, and yielded an AUC of 0.88 (sensitivity of 76% with a specificity of 88%) in the test set. Analysis of the full patient sample set is near completion. In October 2013, OncoCyte entered into a Sponsored Research Agreement with The Wistar Institute to identify, develop and test potential lung cancer biomarkers collaboratively with Dr. Showe's laboratory. OncoCyte has exercised options to obtain exclusive licenses to any inventions, discoveries or technology developed in the course of the collaborative research, including the technology presented and expects to negotiate definitive license agreements with Wistar.
BioTime, Inc. and OncoCyte Corporation Announces Initial Data from Ongoing Clinical Study of Collagen Type X as A Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers
Apr 20 15
BioTime, Inc. and OncoCyte Corporation announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx™, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The controlled study, initiated at Scottsdale Medical Imaging Laboratories in Scottsdale, AZ, is ongoing and has nearly completed enrollment of over 600 patients. The goal of this study is to assess the performance of PanC-Dx™ in discriminating patients with malignant breast lesions from those with negative findings or benign findings. Study investigators are collecting blood samples from patients undergoing screening or diagnostic mammography. Patient blood samples are being assessed for levels of OncoCyte’s PanC-Dx™ markers, including the concentration of the protein COL10A1, using proprietary assays and the results are compared to radiological and pathology findings. Expression of the gene COL10A1 at an mRNA level has been shown in past studies to be significantly elevated in multiple and diverse malignant tumor types including cancers of the breast, stomach, colon, lung, bladder, pancreas, and ovaries. In addition, the protein was shown to be specifically localized within tumor vasculature. Early data showed that PanC-Dx™ identified a mean concentration of COL10A1 protein in sera of breast cancer patients (n=33) that was 35% higher than the mean COL10A1 value in sera of normal individuals (n=32). No significant differences were noted when comparing breast cancer patients to patients with confirmed benign disease suggesting that additional biomarkers may be necessary to discriminate these two populations. Based on this data, PanC-Dx™ offered improved performance as compared to the commercially available enzyme-linked immunosorbent assay (ELISA) manufactured with polyclonal antibodies that study investigators previously used in analyzing over 400 serum samples from healthy volunteers and cancer patients. Evaluation of the performance of PanC-Dx™ demonstrated 86% area-under-the-curve (AUC) of the Receiver Operating Characteristic (ROC) curve, which determines the level of specificity and sensitivity of the product. The polyclonal ELISA demonstrated 74% AUC of the ROC curve.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 8, 2015